Stocks and Investing
Stocks and Investing
Thu, April 7, 2016
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Wed, April 6, 2016
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Hartaj Singh Maintained (SRPT) at Buy with Increased Target to $60 on, Apr 6th, 2016
Hartaj Singh of Oppenheimer, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Increased Target from $45 to $60 on, Apr 6th, 2016.
Hartaj has made no other calls on SRPT in the last 4 months.
There is 1 other peer that has a rating on SRPT. Out of the 1 peers that are also analyzing SRPT, all agrees with Hartaj's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Brian Abrahams of "RBC Capital" Downgraded from Buy to Hold and Decreased Target to $15 on, Tuesday, January 19th, 2016
Contributing Sources